Cargando…

Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer

The aim of the current study was to determine the clinical significance according to the subtypes of epidermal growth factor receptor (EGFR) mutations and presence of KRAS mutations in operable non-small-cell lung cancer (NSCLC). We sequenced exons 18-21 of the EGFR tyrosine kinase domain and examin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Na, Im II, Rho, Jin Kyung, Choi, Yun Jung, Kim, Cheol Hyeon, Koh, Jae Soo, Ryoo, Baek-Yeol, Yang, Sung Hyun, Lee, Jae Cheol
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2007
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693627/ https://www.ncbi.nlm.nih.gov/pubmed/17596643 http://dx.doi.org/10.3346/jkms.2007.22.3.393

Ejemplares similares

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
por: Kim, Seo Yun, et al.
Publicado: (2019)

Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer
por: Kim, Seo Yun, et al.
Publicado: (2017)

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
por: So, Kwang Sup, et al.
Publicado: (2014)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
por: Li, Meihui, et al.
Publicado: (2022)

Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer
por: Jin, Ying, et al.
Publicado: (2016)

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
por: Kim, Ho Cheol, et al.
Publicado: (2019)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
por: Lee, Woohyung, et al.
Publicado: (2020)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Jung, Sangyong, et al.
Publicado: (2021)

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Not All EGFR Exon 20 Insertions Are Created Equal
por: Lin, Yen-Ting, et al.
Publicado: (2020)

Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection
por: Lim, Dong-Hoon, et al.
Publicado: (2023)

Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines
por: Ji, Wonjun, et al.
Publicado: (2020)

Infrared reflectance image-guided laser photocoagulation of telangiectatic capillaries in persistent diabetic macular edema
por: Roh, Hyeon Cheol, et al.
Publicado: (2021)

Exon skipping-rich transcriptomes of animals reflect the significance of exon-shuffling in metazoan proteome evolution
por: Patthy, Laszlo
Publicado: (2019)

Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
por: Kim, Joo Hoon, et al.
Publicado: (2010)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Clinical research on the efficacy and safety of thread-embedding acupuncture for treatment of herniated intervertebral disc of the lumbar spine: a protocol for a multicenter, randomized, patient–assessor blinded, controlled, parallel, clinical trial
por: Goo, Bonhyuk, et al.
Publicado: (2018)

EV-based EGFR genotyping in bronchoalveolar lavage fluid—a step forward from blood?
por: Ji, Wonjun, et al.
Publicado: (2020)

Inhibition of Melanosome Transport by Inducing Exon Skipping in Melanophilin
por: Kim, Jin Young, et al.
Publicado: (2023)

Poor prognostic factors in patients who underwent surgery for acute non-occlusive ischemic colitis
por: Noh, Minsu, et al.
Publicado: (2015)

Erratum to: Poor prognostic factors in patients who underwent surgery for acute non-occlusive ischemic colitis
por: Noh, Minsu, et al.
Publicado: (2016)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
por: Yoo, Changhoon, et al.
Publicado: (2021)

Identification of protein features encoded by alternative exons using Exon Ontology
por: Tranchevent, Léon-Charles, et al.
Publicado: (2017)

Clinicopathological Features of Primary Jejunoileal Tumors
por: Kim, Chang Hyun, et al.
Publicado: (2010)

Targeting branch sites of new exons?
por: Vorechovsky, Igor
Publicado: (2012)

The Emergence of Alternative 3′ and 5′ Splice Site Exons from Constitutive Exons
por: Koren, Eli, et al.
Publicado: (2007)

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
por: Su, Jian, et al.
Publicado: (2017)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
por: Yoo, Changhoon, et al.
Publicado: (2019)

Therapeutic Drug Concentrations of Teicoplanin in Clinical Settings
por: Nah, So-Yun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_50emqhgnr3o0731bs6lu2ej8j4